Astrazeneca Vaccine Safety For Stroke Patients: What's The Verdict?

The AstraZeneca COVID-19 vaccine has been deemed safe and effective by the European Union's drug regulator, despite rare cases of blood clots in a small number of recipients. The benefits of the vaccine outweigh the risks, and there is no evidence to suggest that people who have had a stroke are at higher risk of complications. In fact, experts recommend that people with a history of heart disease get vaccinated as they are at an increased risk of serious harm or death from COVID-19.

AstraZeneca vaccine safe for stroke patients over 50

The AstraZeneca vaccine has been linked to rare but serious cases of blood clotting, which has resulted in some countries advising against its use for people under 50. However, experts agree that the vaccine is safe for people over 50, including those who have had a stroke.

In Australia, the government advised against administering the AstraZeneca vaccine to most people under 50 following a number of fatal blood clots in Europe. Instead, the Pfizer vaccine is preferred for this age group. Professor Paul Kelly, the country's Chief Medical Officer, stated that the decision was based on the increased risk of complications from COVID-19 with age, as well as the "potentially lower risk" of rare blood clots in older individuals.

Similarly, the UK recommended that the AstraZeneca vaccine not be given to those under 30 if an alternative is available. Professor Jonathan Van-Tam, England's Deputy Chief Medical Officer, clarified that this was not because the vaccine is unsafe for younger people, but because the risk/benefit balance may be more finely balanced due to their lower risk of dying from COVID-19.

Health experts in Australia have affirmed that the AstraZeneca vaccine is safe for people over 50, including those who have previously had a heart attack or stroke. Robert Graham, head of the cardiac receptor biology laboratory at the Victor Chang Cardiac Research Institute, stated that blood clotting associated with the vaccine seems to be confined to a very small number of young women under 50. He advised that it is not an issue for older people who may have had a heart attack. This sentiment was echoed by Bruce Willett, vice-president of the Royal Australian College of General Practitioners, who emphasised the rarity of side effects and the equal protection provided by the AstraZeneca vaccine compared to other vaccines.

While the AstraZeneca vaccine has been linked to rare blood clotting events, these clots are different from typical clots. Garry Jennings, Heart Foundation chief medical adviser and cardiologist, stated that there is no evidence to suggest that people who have had a heart attack or cardiac arrest are at higher risk of complications from any of the COVID-19 vaccines compared to others. He encouraged people with heart disease to get vaccinated with whichever vaccine is offered to them as soon as possible.

In summary, while there have been concerns about the AstraZeneca vaccine and its potential link to rare blood clots, experts agree that it is safe for individuals over 50, including those with a history of stroke. The benefits of protection against COVID-19 outweigh the potential risks, especially in older age groups who are more vulnerable to severe disease.

AstraZeneca vaccine safe for those on blood thinners

The AstraZeneca vaccine has been linked to rare blood clots, particularly in younger women under 50. However, experts agree that the vaccine is safe for those who have had a heart attack or are taking blood thinners.

Robert Graham, head of the cardiac receptor biology laboratory at the Victor Chang Cardiac Research Institute, said that people recovering from a heart attack should not be concerned about getting the AstraZeneca vaccine. He added that the blood clots linked to the vaccine seem to be confined to a very small number of people, primarily young women under 50. Bruce Willett, vice-president of the Royal Australian College of General Practitioners, agreed, stating that the side effects are very rare, especially in older, more vulnerable individuals.

People who take blood thinners can safely receive the AstraZeneca vaccine, according to Professor Graham. While they may experience a little more bleeding or bruising under the skin, this is not a reason to avoid the vaccine. Dr. Willett concurred, noting that those taking blood thinners have underlying conditions that put them at higher risk, and they would benefit more from being vaccinated. However, he recommended that older individuals with complex medical histories consult their doctors before vaccination.

In India, the fact sheets of Covaxin and Covishield, the two vaccines in use at the time, were revised to allow people on blood thinners like aspirin and clopidogrel to receive the vaccines. The Indian Council of Medical Research (ICMR) director-general, Dr. Balram Bhargava, clarified that while those on anticoagulants like heparin may have a tendency to bleed and develop a local hematoma, this is a relative contraindication, and such medications can be stopped for a day or two before vaccination.

While the AstraZeneca vaccine has been associated with rare blood clots, experts agree that it is safe for those who have had heart attacks or are taking blood thinners. It is always recommended to consult with a healthcare professional for personalized advice, especially for those with complex medical histories.

AstraZeneca vaccine safe for those with heart disease

There have been concerns about the safety of the AstraZeneca vaccine, particularly regarding its link to blood clots. However, experts say that the majority of people with a history of heart disease should still be vaccinated.

Blood Clots and the AstraZeneca Vaccine

The Oxford/AstraZeneca vaccine has been linked to a rare blood clotting disorder called vaccine-induced thrombosis and thrombocytopenia (VITT). This condition involves blood clots accompanied by low blood platelet counts. While rare, these clots can be deadly.

Heart Disease and COVID-19 Risk

People with heart disease are at an increased risk of serious harm or death if they contract COVID-19. Heart disease patients, especially those with heart failure, are encouraged to get vaccinated as soon as possible to reduce this risk.

AstraZeneca Vaccine Safety for Heart Disease Patients

Despite the concerns about blood clots, experts advise that the AstraZeneca vaccine is still safe for most people with heart disease. Robert Graham, head of the cardiac receptor biology laboratory at the Victor Chang Cardiac Research Institute, states that the blood clots linked to the vaccine mainly affect young women under 50, and it's "not really an issue" for older individuals who may have had a heart attack.

Bruce Willett, vice-president of the Royal Australian College of General Practitioners, echoes this sentiment, emphasizing that the side effects are "very rare" and that the AstraZeneca vaccine provides "at least equal protection" in terms of hospitalization, ICU admission, and death compared to other vaccines.

Precautions and Recommendations

While the AstraZeneca vaccine is generally considered safe for heart disease patients, it is always advisable to consult with a healthcare professional before getting vaccinated, especially for those with complex medical histories or those taking blood thinners.

In conclusion, while there have been concerns about the AstraZeneca vaccine's link to blood clots, experts advise that it is still safe for most people with heart disease to receive the vaccine. The benefits of protection against COVID-19, which poses a higher risk to those with heart conditions, are considered to outweigh the rare side effects. However, it is important to consult with a healthcare professional for personalized advice.

AstraZeneca vaccine safe for those with a history of blood clots

The AstraZeneca vaccine is considered safe for those with a history of blood clots. The blood clots observed in people post-vaccination are different from typical clots. They are characterised by a rare condition called thrombosis with thrombocytopenia syndrome (TTS) or vaccine-induced thrombosis and thrombocytopenia (VITT). TTS is caused by an abnormal immune response, resulting in the development of an antibody directed at the platelets, which causes them to become hyperactive and triggers blood clots in unusual places, such as the brain or abdomen.

The Australian Technical Advisory Group on Immunisation (ATAGI) has advised that the AstraZeneca vaccine is safe for those with a history of blood clots. They estimate the risk of TTS in Australia at around 1.6 in 100,000 doses of the AstraZeneca vaccine administered to people aged 50 and older. However, it is important to note that Australian guidelines recommend that certain people should avoid the AstraZeneca vaccine and opt for the Pfizer jab instead. These include individuals who have had previous episodes of heparin-induced thrombocytopenia, venous blood clots in their brain or abdomen, or a rare antibody-driven clotting disease called antiphospholipid syndrome. Additionally, people under 50 are advised to choose the Pfizer vaccine.

The clots associated with the AstraZeneca vaccine are different from those that cause heart attacks and strokes. People with a history of these conditions or deep vein thrombosis and pulmonary embolism do not appear to be at increased risk from the AstraZeneca vaccine. In fact, this group may be at greater risk from COVID-19 and should not delay getting vaccinated.

While the AstraZeneca vaccine is generally considered safe for those with a history of blood clots, it is always recommended to consult with a healthcare professional to discuss individual circumstances and make an informed decision.

AstraZeneca vaccine safe for those on medication that increases blood clot risk

The AstraZeneca COVID-19 vaccine has been found to slightly increase the risk of intracranial thrombosis events, particularly in adults under 70. However, the benefits of the vaccine in preventing hospitalisation and death from COVID-19 are believed to outweigh this small increased risk.

Two studies published in PLOS Medicine analysed over 30 million UK patients. The first study, led by William Whiteley of the University of Edinburgh, found a small increase in the rate of intracranial venous thrombosis (ICVT) in people under 70 within 28 days of vaccination with the AstraZeneca vaccine. This corresponded to an estimated excess risk of 0.9–3 per million, about twice the rate compared to unvaccinated people.

The second study, led by Steven Kerr, also from the University of Edinburgh, found a small elevated risk of cerebral venous sinus thrombosis (CVST) events—a rare type of blood clot in the brain—following vaccination with the AstraZeneca vaccine. This corresponded to one additional event per 4 million people vaccinated, again about twice the risk compared to unvaccinated people.

Despite these findings, the teams behind both studies emphasised that the benefits of the vaccine far outweigh any potential risks. The low number of overall CVST and other subtypes of thrombosis events, even in large cohorts, makes precise estimates of the risks difficult.

In terms of those on medication that increases blood clot risk, Professor Robert Graham of the Victor Chang Cardiac Research Institute states that there is no evidence that the AstraZeneca vaccine will cause issues even if you have had blood clots before. He notes that the type of clotting observed in those who have had the AstraZeneca vaccine is different from typical clots.

Professor Graham encourages people who are on medications that increase blood clot risk to talk to their doctor before being vaccinated, as there is a lack of information currently available. However, he is not overly concerned, as the clots caused by these medications typically occur in the leg, whereas the clots observed after the AstraZeneca vaccine seem to be caused by a different mechanism.

Overall, while there is a slightly elevated risk of blood clots associated with the AstraZeneca vaccine, particularly in younger patients, the benefits of the vaccine in preventing severe COVID-19 outcomes are believed to outweigh this small increased risk. For those on medication that increases blood clot risk, it is recommended to consult with a healthcare professional before receiving the AstraZeneca vaccine, but there is currently no evidence of increased risk, and the clots caused by the vaccine seem to be of a different type.

Frequently asked questions